Fig. 4
Forest plot of overall symptom duration after drug administration: maoto vs. neuraminidase inhibitors (NAIs). The duration of symptoms does not differ significantly between maoto and NAIs. The heterogeneity is not significant (P > 0.1, I2 < 75%), and a fixed-effect model is used for this outcome. Kawamura [19, 23] defined the duration of symptoms as the time until complete disappearance of the symptoms, while Nabeshima et al. [25] defined it as the time during which the symptom score was over the cut-off point for symptoms